June 16, 2020 / 4:08 PM / 25 days ago

BRIEF-ABRE Study Meets Primary Safety And Effectiveness Endpoints

June 16 (Reuters) - Medtronic PLC:

* ABRE STUDY MEETS PRIMARY SAFETY AND EFFECTIVENESS ENDPOINTS

* MEDTRONIC SELF-EXPANDING VENOUS STENT DEMONSTRATES FAVORABLE OUTCOMES IN PATIENTS WITH VENOUS OUTFLOW OBSTRUCTION

* STUDY MET ITS PRIMARY SAFETY ENDPOINT WITH A 2.0% (4/200) RATE OF MAJOR ADVERSE EVENTS WITHIN 30 DAYS

* ABRE STUDY MEETS PRIMARY SAFETY AND EFFECTIVENESS ENDPOINTS

* DATA DEMONSTRATED A FREEDOM FROM CLINICALLY DRIVEN TARGET LESION REVASCULARIZATION RATE OF 92.4%

* NO STENT FRACTURES AND NO DELAYED STENT MIGRATION OBSERVED WITHIN 12 MONTHS IN STUDY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below